Clinical Trial Update: Preliminary Evaluation of the Safety and Tolerability of SPOT-mRNA01 Subcutaneously Administered in Healthy Subjects [Phase 1]

View source ↗

Summary

This Phase 1 trial update reports the safety and tolerability evaluation of SPOT-mRNA01 administered subcutaneously in healthy subjects, with the study status l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Skin Aging

Drugs mentioned

• SPOT-mRNA01

Snippet

Sponsor: SIPO Biotechnology Co. Ltd. | Conditions: Skin Aging | Phase 1 | Status: NOT_YET_RECRUITING